Skip to main content

Company name

Farmacorp S.A. (“Farmarcorp” o la “Compañía)

Project number

13144-01

Category C projects are those that are likely to result in very limited or no adverse environmental or social impacts or risks.

E&S category
tooltip

C

Country

Bolivia

Sector

Manufacturing

Status

In implementation

Disclosed date

05/21/2021

Projected date at which a project will be put forward for the Board of Executive Directors’ approval.

Projected board date
tooltip

10/22/2021

Approval date

10/22/2021

Signed date

12/21/2023

Sponsoring entity

N/A

Investment Operations Department Contact

N/A

Investment type

Syndicated amount

N/A

Financing amount

USD $ 5,000,000

Currency

USD

Project scope and objective

This transaction involves a revolving and uncommitted line of credit in favor of Farmacorp S.A. (hereinafter "Farmacorp" or the "Company") in Bolivia. These funds will be used to import medical and hospital supplies from foreign suppliers.

 

 

Farmacorp is the largest and most experienced retail drugstore business in Bolivia. The Company sells drugs (82%), food, cosmetics and miscellaneous personal care and wellness products. Farmacorp sells private or own brand products that represent 5% of its range. However, it mostly represents international brands in Bolivia, including GNC Live Well, About Time, Foster Grant, Jockey, Ubu and Scunci. The Company has 70 years’ experience and its market share of the drugstore chain segment is about 46%. Its stores are concentrated in the Santa Cruz and Cochabamba departments, but it also has stores in La Paz, Tarija and Oruro.

 

 

For inquiries, comments and information requests about the project

Request information

Learn more about how we provide private-sector solutions in the region .

Environmental and social review

IDB Invest conducts an environmental and social due diligence (ESDD) commensurate with the nature, scale, and stage of the project, and with its level of environmental and social risks and impacts. The ESDD will confirm the project E&S categorization and assess the project with respect to the client requirements in IDB Invest Environmental and Social Sustainability Policy. The results of the ESDD, including any identified gaps are described in the Environmental and Social Review Summary (ESRS) provided below. For projects approved as of 2016, any gaps with respect to IDB Invest's Environmental and Social Sustainability Policy at the time of the ESDD are addressed in the Environmental and Social Action Plan (ESAP) presented below, to comply with the date mentioned above.

FARMACORP-ENVIRONMENTAL AND SOCIAL REVIEW SUMMARY (ESRS)

174.1 Kb

FARMACORP-ENVIRONMENTAL AND SOCIAL ACTION PLAN (ESAP)

112.6 Kb

For inquiries, comments and information requests about the project

Request information

Learn more about how we provide private-sector solutions in the region .

Contact information

For inquiries, comments and information requests about the project

Request information

Alternatively, you may also use the following contact information :

Client Contact

EMAIL

N/A

PHONE NUMBER

N/A

POST OFFICE ADDRESS

N/A

IDB Invest Contact

EMAIL

requestinformation@idbinvest.org

PHONE

+1(202)-566-4566

ADDRESS

1350 New York Ave NW, Washington, DC 20005

For inquiries, comments and information requests about the project

Request information

Learn more about how we provide private-sector solutions in the region .